According to IQVIA, 110 biological medicines in Europe are set to lose patent protection by 2032. This has further strengthened Biokinetica’s interest in supporting biosimilar development.
We are proud to support bringing more affordable treatments but also aligns with sustainable and cost-effective strategies in the evolving pharmaceutical landscape.
